The EMPA-REG study: What has it told us? A diabetologist’s perspective-Reference-Cited by-同舟云学术

The EMPA-REG study: What has it told us? A diabetologist’s perspective

Published:2016-01 Issue:1 Volume:30 Page:1-2
ISSN:1056-8727
Container-title:Journal of Diabetes and its Complications
language:en
Short-container-title:Journal of Diabetes and its Complications

Author:

DeFronzo Ralph A.

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference16 articles.

1. Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes;Abdul-Ghani;Endocrine Reviews,2011

2. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus;Cherney;Cardiovascular Diabetology,2014

3. Improved left ventricular diastolic function (LVDF) following pioglitazone therapy is strongly related to increased myocardial insulin sensitivity;Clarke;Diabetes,2014

4. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial;Dormandy;Lancet,2005

5. Glucose control and vascular complications in veterans with type 2 diabetes;Duckworth;NEJM,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator;Cardiovascular Diabetology;2024-01-06

2. Beneficial effects of SGLT2 inhibitor on metabolic inflexibility and visceral fat amount in animal model of obese type 2 diabetes;Heliyon;2022-10

3. Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial;BMJ Open;2022-08

4. Beneficial Effects of SGLT2 Inhibitor on Metabolic Inflexibility and Visceral Fat Amount in an Animal Model of Obese Type 2 Diabetes;SSRN Electronic Journal;2022

5. Empagliflozin in the elderly;Gériatrie et Psychologie Neuropsychiatrie du Viellissement;2021-06